EPS Bio Technology Balance Sheet Health
Financial Health criteria checks 6/6
EPS Bio Technology has a total shareholder equity of NT$313.2M and total debt of NT$13.6M, which brings its debt-to-equity ratio to 4.4%. Its total assets and total liabilities are NT$565.1M and NT$251.9M respectively. EPS Bio Technology's EBIT is NT$33.7M making its interest coverage ratio -44. It has cash and short-term investments of NT$151.3M.
Key information
4.4%
Debt to equity ratio
NT$13.63m
Debt
| Interest coverage ratio | -44x |
| Cash | NT$151.32m |
| Equity | NT$313.21m |
| Total liabilities | NT$251.87m |
| Total assets | NT$565.09m |
Recent financial health updates
No updates
Recent updates
Should You Or Shouldn't You: A Dividend Analysis on EPS Bio Technology Corp. (GTSM:4183)
Apr 16
Will EPS Bio Technology (GTSM:4183) Multiply In Value Going Forward?
Mar 20Here's Why We Think EPS Bio Technology's (GTSM:4183) Statutory Earnings Might Be Conservative
Feb 22Do Fundamentals Have Any Role To Play In Driving EPS Bio Technology Corp.'s (GTSM:4183) Stock Up Recently?
Feb 01
Should EPS Bio Technology Corp. (GTSM:4183) Be Part Of Your Dividend Portfolio?
Jan 04Is EPS Bio Technology (GTSM:4183) Likely To Turn Things Around?
Dec 14We Think EPS Bio Technology's (GTSM:4183) Statutory Profit Might Understate Its Earnings Potential
Nov 23Financial Position Analysis
Short Term Liabilities: 4183's short term assets (NT$389.4M) exceed its short term liabilities (NT$142.2M).
Long Term Liabilities: 4183's short term assets (NT$389.4M) exceed its long term liabilities (NT$109.6M).
Debt to Equity History and Analysis
Debt Level: 4183 has more cash than its total debt.
Reducing Debt: 4183's debt to equity ratio has reduced from 9% to 4.4% over the past 5 years.
Debt Coverage: 4183's debt is well covered by operating cash flow (72.7%).
Interest Coverage: 4183 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 05:24 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
EPS Bio Technology Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pinghan Hsieh | Capital Securities Corporation |